Your Health, We Care
Release date: 2024-08-13 17:56:34 Recommended: 118
Venetoclax is a small molecule drug approved in combination with azacitidine for the treatment of acute myeloid leukemia. Initially indicated as chronic lymphocytic leukemia, it has now expanded to include a variety of hematologic cancers.
Before purchasing and using a drug, patients should understand the dosage requirements of the drug so that they can take it as prescribed:
For chronic lymphocytic leukemia, venetoclax is given in escalating doses of 20 mg daily in week 1, 50 mg daily in week 2, 100 mg daily in week 3, 200 mg daily in week 4, and 400 mg daily in weeks 5 and beyond.
For acute myeloid leukemia (AML), the escalation regimen of venetoclax begins on day 1 of cycle 1 and lasts for 3 to 4 days: 100 mg daily on day 1, 200 mg daily on day 2, and 400 mg daily on day 3. From day 4 onwards, patients are given 400 mg (in combination with azacitidine or decitabine) or 600 mg (in combination with low-dose cytarabine) daily in 28-day cycles.
According to the drug instructions, precautions for the use of drugs include, but are not limited to, the following:
During venetoclax treatment, patients are at risk of fatal and serious infections, such as pneumonia and sepsis, which can be life-threatening.
Before, during, and after venetoclax treatment, live attenuated vaccine should be avoided until B-cell function is restored. There are currently no research data on the safety and efficacy of such vaccines given during or after venetoclax treatment, vaccination may be compromised, and vaccination is not recommended.
Patients should learn more about the precautions for drug use, and the specific populations for venetoclax will be described below:
There is no data on whether venetoclax is passed to the infant through breast milk, or what effect it has on breastfed infants and breast milk production. Breastfeeding women are advised to avoid breastfeeding while using venetoclax or to consult a physician professional for individualized medication advice.
For women of childbearing potential who are planning to become pregnant or may become pregnant, as well as men of childbearing age, appropriate contraception should be used during venetoclax and for some time after discontinuation, given the potential effects that the drug may have on male fertility.
[Warm tips] As an important therapeutic drug, venetoclax must be used under the guidance of a professional doctor. Each patient's individual situation and condition is different, and doctors will develop a personalized treatment plan based on the patient's specific situation.
